Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Artrya Limited ( (AU:AYA) ) has provided an announcement.
Artrya Limited announced that all resolutions at its Annual General Meeting were passed, reflecting shareholder support for the company’s strategic direction. This development underscores Artrya’s commitment to leveraging its AI-powered platform for coronary artery disease management and reinforces its position in the medical technology industry.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions to enhance the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in diagnosing patients more accurately and efficiently. Artrya is committed to advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 965,503
Technical Sentiment Signal: Buy
Current Market Cap: A$580.2M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.